Query: High-content, high-throughput assay strategies for screening anti-fibrotic compounds in renal cell culture, including reporter constructs for TGF-beta signalling, collagen deposition assays, hydroxyproline assays, immunofluorescence quantification of alpha-SMA, ECM remodelling metrics

High-content, high-throughput assay strategies for screening anti‐fibrotic compounds in renal cell culture rely on a multiparametric approach that integrates phenotypic readouts of fibroblast activation and extracellular matrix (ECM) remodeling with sensitive measures of key fibrogenic signaling pathways, most notably TGF‐β signaling.

One critical element is the incorporation of TGF‐β reporter constructs. These genetically engineered constructs provide a real‐time and quantitative readout of TGF‐β pathway activation by linking a reporter gene—for example, luciferase—to TGF‐β responsive elements. Although not always detailed explicitly in every renal fibrosis model, the utility of such constructs has been emphasized in related high-content screening platforms, supporting early detection of fibrogenic signaling events that precede phenotypic changes (palano2021invitroassays pages 2-3, song2021identificationofhepatic pages 11-11).

Another cornerstone of these assays is the quantification of collagen deposition. Immunofluorescence assays are routinely applied, where antibodies targeting collagen type I enable visualization and quantification of deposited ECM proteins. High-content imaging systems—such as the CellInsight HCS microscope—capture images that are analyzed for mean fluorescence intensity (MFI), offering both spatial resolution and robust signal-to-noise ratios. This strategy was exemplified in pulmonary fibroblast models, and similar methods are readily adaptable to renal cell cultures using patient-derived fibroblasts and epithelial cells to ensure physiological relevance (good2019ahighcontent pages 5-7, tasinato2024developmentofan pages 195-197).

In tandem with direct immunofluorescence, biochemical assays such as the hydroxyproline assay are used to quantify mature collagen content. Hydroxyproline, a post-translationally modified amino acid specifically enriched in collagen, serves as a surrogate marker for ECM accumulation. Despite being a bulk assay compared to image-based quantification, hydroxyproline analysis provides complementary quantitative data that, when integrated with immunofluorescence measurements, validates the extent of fibrosis at the protein level (palano2021invitroassays pages 3-5, sieber2018novelhigh–throughputmyofibroblast pages 2-4).

A further assay endpoint involves the immunofluorescence quantification of α-smooth muscle actin (α-SMA). Expression of α-SMA is a definitive marker for the differentiation of fibroblasts into myofibroblasts—a hallmark event in fibrogenesis. High-content imaging not only quantifies the overall intensity of α-SMA staining but, with advanced image analysis, can also assess the organization and distribution of stress fibers within cells. This multiparametric readout is instrumental in distinguishing subtle differences between fibrotic and non-fibrotic states and enhances screening sensitivity for candidate compounds (cardonatimoner2025dressedincollagen pages 16-17, palano2020focusonfibroblasts pages 41-45).

ECM remodeling metrics further extend the assay’s depth. Beyond collagen, various studies have quantified additional ECM components—such as fibronectin and collagen subtypes—using immunofluorescence, biochemical assays, and decellularization protocols followed by fluorescent staining. Moreover, advanced imaging techniques allow for the analysis of ECM architecture, including fibril organization and branching point density, which provides insight into the qualitative changes occurring during fibrosis (holdsworth2017quantitativeandorganisational pages 5-7, gerckens2023discoveryofnew pages 61-67).

Finally, coupling these endpoints with sophisticated cell culture models, such as 3D co-culture systems of human proximal tubule cells and renal fibroblasts, further refines the assay. Such models recapitulate critical aspects of the renal microenvironment—including epithelial barrier function and fibroblast-epithelial crosstalk—and can be integrated with high-content imaging, TEER measurements, and metabolic assays to capture both functional and structural alterations induced by pro-fibrotic stimuli (tasinato2024developmentofan pages 197-200, tasinato2024developmentofan pages 43-45).

Overall, combining TGF-β reporter constructs, collagen deposition assays, hydroxyproline quantification, immunofluorescence-based detection of α-SMA, and detailed ECM remodeling metrics yields a robust and comprehensive high-content, high-throughput screening platform suited for the discovery of anti-fibrotic compounds in relevant renal cell culture models (vijayaraj2019modelingprogressivefibrosis pages 23-24, palano2021invitroassays pages 3-5).

References:
1. (good2019ahighcontent pages 5-7): Robert B. Good, Jessica D. Eley, Elaine Gower, Genevieve Butt, Andrew D. Blanchard, Andrew J. Fisher, and Carmel B. Nanthakumar. A high content, phenotypic ‘scar-in-a-jar’ assay for rapid quantification of collagen fibrillogenesis using disease-derived pulmonary fibroblasts. BMC Biomedical Engineering, Jun 2019. URL: https://doi.org/10.1186/s42490-019-0014-z, doi:10.1186/s42490-019-0014-z. This article has 28 citations.

2. (tasinato2024developmentofan pages 195-197): E Tasinato. Development of an in vitro 3d model of the proximal tubule interstitial interface as a high throughput renal fibrosis assay platform. Unknown journal, 2024.

3. (tasinato2024developmentofan pages 43-45): E Tasinato. Development of an in vitro 3d model of the proximal tubule interstitial interface as a high throughput renal fibrosis assay platform. Unknown journal, 2024.

4. (vijayaraj2019modelingprogressivefibrosis pages 23-24): Preethi Vijayaraj, Aspram Minasyan, Abdo Durra, Saravanan Karumbayaram, Mehrsa Mehrabi, Cody J. Aros, Sarah D. Ahadome, David W. Shia, Katherine Chung, Jenna M. Sandlin, Kelly F. Darmawan, Kush V. Bhatt, Chase C. Manze, Manash K. Paul, Dan C. Wilkinson, Weihong Yan, Amander T. Clark, Tammy M. Rickabaugh, W. Dean Wallace, Thomas G. Graeber, Robert Damoiseaux, and Brigitte N. Gomperts. Modeling progressive fibrosis with pluripotent stem cells identifies an anti-fibrotic small molecule. Cell Reports, 29:3488-3505.e9, Dec 2019. URL: https://doi.org/10.1016/j.celrep.2019.11.019, doi:10.1016/j.celrep.2019.11.019. This article has 22 citations and is from a highest quality peer-reviewed journal.

5. (cardonatimoner2025dressedincollagen pages 16-17): Maria Cardona-Timoner, Rita N. Gomes, and Diana S. Nascimento. Dressed in collagen: 2d and 3d cardiac fibrosis models. International Journal of Molecular Sciences, 26:3038, Mar 2025. URL: https://doi.org/10.3390/ijms26073038, doi:10.3390/ijms26073038. This article has 0 citations and is from a peer-reviewed journal.

6. (gerckens2023discoveryofnew pages 61-67): MW Gerckens. Discovery of new cinnamic acid amides as novel antifibrotic drugs. Unknown journal, 2023.

7. (holdsworth2017quantitativeandorganisational pages 5-7): Gill Holdsworth, Hélène Bon, Marianne Bergin, Omar Qureshi, Ross Paveley, John Atkinson, Linghong Huang, Roohi Tewari, Breda Twomey, and Timothy Johnson. Quantitative and organisational changes in mature extracellular matrix revealed through high-content imaging of total protein fluorescently stained in situ. Scientific Reports, Aug 2017. URL: https://doi.org/10.1038/s41598-017-10298-x, doi:10.1038/s41598-017-10298-x. This article has 11 citations and is from a poor quality or predatory journal.

8. (palano2020focusonfibroblasts pages 41-45): G Palano. Focus on fibroblasts: development, plasticity, and therapeutic challenges in the cardiac fibroblast lineage. Unknown journal, 2020.

9. (palano2021invitroassays pages 2-3): Giorgia Palano, Ariana Foinquinos, and Erik Müllers. In vitro assays and imaging methods for drug discovery for cardiac fibrosis. Frontiers in Physiology, Jul 2021. URL: https://doi.org/10.3389/fphys.2021.697270, doi:10.3389/fphys.2021.697270. This article has 16 citations and is from a peer-reviewed journal.

10. (palano2021invitroassays pages 3-5): Giorgia Palano, Ariana Foinquinos, and Erik Müllers. In vitro assays and imaging methods for drug discovery for cardiac fibrosis. Frontiers in Physiology, Jul 2021. URL: https://doi.org/10.3389/fphys.2021.697270, doi:10.3389/fphys.2021.697270. This article has 16 citations and is from a peer-reviewed journal.

11. (sieber2018novelhigh–throughputmyofibroblast pages 2-4): Patrick Sieber, Anny Schäfer, Raphael Lieberherr, François Le Goff, Manuel Stritt, Richard W. D. Welford, John Gatfield, Oliver Peter, Oliver Nayler, and Urs Lüthi. Novel high–throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via ep2 and ep4 receptors. PLOS ONE, 13:e0207872, Nov 2018. URL: https://doi.org/10.1371/journal.pone.0207872, doi:10.1371/journal.pone.0207872. This article has 32 citations and is from a peer-reviewed journal.

12. (song2021identificationofhepatic pages 11-11): Yeonhwa Song, Sanghwa Kim, Jinyeong Heo, David Shum, Su-Yeon Lee, Minji Lee, A-Ram Kim, and Haeng Ran Seo. Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model. Scientific Reports, May 2021. URL: https://doi.org/10.1038/s41598-021-90263-x, doi:10.1038/s41598-021-90263-x. This article has 17 citations and is from a poor quality or predatory journal.

13. (tasinato2024developmentofan pages 197-200): E Tasinato. Development of an in vitro 3d model of the proximal tubule interstitial interface as a high throughput renal fibrosis assay platform. Unknown journal, 2024.
